Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Aug 23;22(10):89.
doi: 10.1007/s11864-021-00883-8.

Novel and Promising Systemic Treatment Approaches in Mesothelioma

Elizabeth Dudnik #  1   2 , Daniel Reinhorn #  3 , Liran Holtzman  4
Affiliations
Review

Novel and Promising Systemic Treatment Approaches in Mesothelioma

Elizabeth Dudnik et al. Curr Treat Options Oncol. .

Abstract

There was limited progress in the development of novel systemic approaches in the treatment of advanced malignant mesothelioma for years following the publication of the pivotal phase III trial of Vogelzang et al. that established the cisplatin/pemetrexed regimen as a standard 1st-line systemic therapy. Since then, over the last several years, a significant step forward has been made, with incorporation of immune checkpoint inhibitors and anti-angiogenic agents. In addition, better appreciation of mesothelioma biology has allowed detection of novelmolecular therapeutic targets. All the above-mentioned strategies, along with the additional promising approaches represented by adoptive T cell therapy, dendritic cell therapy, cancer vaccines, oncoviral therapy, and agents targeting mesothelin are discussed in this review. The clinical research to identify effective biologic targets and treatment combinations in malignant mesothelioma is ongoing.

Keywords: Anti-angiogenic; CAR T cell; Immune checkpoint inhibitors; MSLN; Mesothelin; Mesothelioma; Targeted.

PubMed Disclaimer

References

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
    1. Lanphear BP, Buncher CR. Latent period for malignant mesothelioma of 604 occupational origin. J Occup Med. 1992;34(7):718–721.605. - PubMed
    1. American Cancer Society. Cancer Facts & Figures. Special 606 Section: Rare Cancers in Adults. Cancer Facts Fig Spec Sect 607. Rare Cancers Adults. 2017:30–39.608.
    1. Curran BD, Sahmoud T, Therasse P, Van MJ, Postmus PE. 609 Giaccone G. Prognostic factors in patients with pleural mesothelioma: 610 the European Organization for Research and Treatment of Cancer 611 Experience. Society. 1998;16(1):145–152.612.
    1. Herndon JE, Green MR, Chahinian AP, Corson JM, Suzuki Y, Vogelzang NJ. Factors predictive of survival among 337 patients with 614 mesothelioma treated between 1984 and 1994 by the Cancer and 615 Leukemia Group B. Chest. 1998;113(3):723–731.616. https://doi.org/10.1378/chest.113.3.723617 . - DOI - PubMed
    1. Edwards JG, Leverment JN, Spyt TJ, Waller DA, O’Byrne KJ. 618 Prognostic factors for malignant mesothelioma in Leicester: validation 619 of EORTC and CALGB scores. Thorax. 1999;54(suppl. 3):731–5.

Publication types

MeSH terms

LinkOut - more resources